Please note, this OEL/ADE monograph also applies to Cefpodoxime proxetil (CAS RN 947692-13-9; 87239-81-4), Cefpodoxime sodium (CAS RN 82619-04-3), and Cefpodoxime monohydrate (CAS RN Not Available). Cefpodoxime proxetil, an oral prodrug of the beta-lactam antibiotic cefpodoxime, is used to treat bacterial infections. It is used to treat bacterial diseases including pneumonia, gonorrhea, and infections of the ear, skin, sinuses, throat, tonsils and urinary tract. Cefpodoxime is a third-generation semi-synthetic beta-lactam cephalosporin that acts by binding to penicillin-binding proteins located in the bacterial cell wall. The binding interrupts the formation of cell wall molecules and results in inhibition of cell wall formation which stops bacterial growth.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Cefpodoxime, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.